Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80)PATENT AND TRADEMARK OFFICE  LIST OF PRIOR ART  CITED BY APPLICANT  (Use several sheets if necessary)				Atty. Docket No. 19746	Serial No. 10/575,928				
				Applicants Larry D. Ward, et al.					
				Filing Date March 22, 2007		Group 1614			
U.S. PAT	ENT	DOCUMENTS							
EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)		
	AA								
	AB		## ***********************************				Marian		
	AC								
	AD								
		Foreign	Date	Country		T			
		Document Number	Date	Country	CLASS	SUBCLASS	TRANSL	ATION NO	
							IES	110	
-									
OTHER P	RIOR	<u> </u>		, Pertinent Pages, Etc.		Janua 1 arta	Tring good		
/L.H./	1.	Dale C. J. et al., "Induction of HIV-1 specific T—helper responses and type 1 cytokine secretion following therapeutic vaccination of macaques with a recombinant fowlpoxvirus co-expressing interferon-gamma", <i>J. Med Primatol</i> 29: 240-247 (2000) XP009004910							
/L.H./	2.	Cao H. et al., "Immunogenicity of a Recombinant Human Immunodeficiency Virus (HIV)-Canarypox Vaccine in HIV-Seronegative Ugandan Volunteers: Results of the HIV Network for Prevention Trials 007 Vaccine Study", <i>Journal of Infectious Diseases 187(6)</i> : 887-895 (2003) XP002457141							
/L.H./	3.	Kim J. J. et al., "In Vivo Engineering of a Cellular Immune Response by Coadministration of IL- 12 Expression Vector with a DNA Immunogen", <i>The Journal of Immunology 158</i> : 816-826 (1997) XP002103878;							
/L.H./	4.	Emery S. et al., "Randomized, Placebo-Controlled, Phase I/IIa Evaluation of the Safety and Immunogenicity of Fowlpox Virus Expressing HIV gag-pol and Interferon-γ in HIV-1 Infected Subjects", <i>Human Vaccines</i> 1(6): 232-238 (2005) XP002457142							
EXAMINER		/Louise Humphrey/		DATE CONSIDERED	11/02/20	11/02/2009			
* EXAMIN	ER; Ini	itial if reference considered	, whether or not	citation is in conformance v with next communication to	vith MPEP 609	; draw line thro	ough citatio	n if not ir	